Seattle Genetics has managed to do something most biotech companies have not. It has created a number of antibody drugs and the results are amazing. People are looking at an entirely new way of treating cancer using the body’s natural defense mechanisms. The antibody-drug conjugates are giving patients a new and much more effective way to fight disease. If these continues to go forward Seattle Genetics is going to bring forward and entirely new way of thinking about cancer. The CEO of Seattle Genetics, Clay Siegall, is behind all of this success, but he isn’t alone and he wants to bring more into the fold.
The Antibody Defense System
Nobody would dispute that the body has a natural defense system perfectly capable of handling the vast majority of tasks. It’s so effective the body can actually reject drugs it needs and end up ruining the bodies of patients. To prevent this Siegall developed a way to insert drugs into the body using antibodies. It’s so effective it allows the body to accept medicine without the reactions that are often seen by many who need cancer treatments.
The Idea Takes Off
The antibody-drug conjugate has gone even in further in terms of getting people the help they need. There are now investors who want to do everything they can to make the dreams of Seattle Genetics a reality and there are others who are interested in the future projects of Clay Siegall. If this continues the potential for medicine is going to be vast. We may actually see a new age of drugs that specifically use the immune system to boost their effectiveness and provide patients with a quality of life they have never seen before.
The Future Of Seattle Genetics
Seattle Genetics has a future going for it. The company has made so much progress and continues to impress with new releases that improve vastly upon their initial workings. People clearly wanted this and it seems that Seattle Genetics is doing a good job of providing innovation in medicine long sought after in today’s market.
In 1998, Clay Siegall co-founded Seattle Genetics and is currently the chief executive officer, president, and chairman of the board of the organization. Siegall is a trained scientist with a focus on targeted cancer therapies. He established Seattle Genetics on the background of rigorous research, scientific innovation, passion for assisting patients, and drug development practices. Siegall has spearheaded the organization to its present leadership status by developing ADCs- antibody drug conjugates and securing the approval of the 2011 FDA for its first ADC item ADCETRIS (brentuximab vedotin). By working together with Takeda Pharmaceutical Company, the name (ADCETRIS) is currently a world brand that has been accepted in over 65 countries. The organization (Seattle Genetics) is also developing a diverse ADCs proprietary for Cancer treatment.
Under the headship of Clay Siegall, Seattle Genetics has acquired multiple strategic licenses while applying its ADC technology. The organization currently works together with other firms such as Genentech (Roche), Pfizer, AbbVie, and GlaxoSmithKline. Across collaborating and internal programs, there are over 20 ADCs within clinical development exercises that are utilizing Seattle Genetics’ technology. Another key achievement of Siegall in Seattle Genetics is the spearheading of capital-raising practices that have secured over $1.2 billion through private and public financings, notwithstanding its first public offering in 2001.
Before he co-founded Seattle Genetics, Siegall operated in other companies, which added to his experience. For instance, from 1988 to 1991, he worked at National Cancer Institute and from 1991 to 1997, he operated at the Bristol-Myers Squibb Pharmaceutical Research Institute. He is also part of the board of directors of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and Washington Roundtable. Siegall is also a recipient of several awards.
According to Siegall, the idea of Seattle Genetics came from the desire to offer patients better treatment services after watching his dad suffer from cancer, which later killed him. It is at this time that he realized that the oncology sector and cancer treatment centers had limited tools. After earning a Doctorate at George Washington University, he later learned how to operate a Company after working with various organizations. His goal is to offer better treatment to cancer patients to save lives.